相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer
Nicola Napoli et al.
BONE (2013)
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
R. Rizzoli et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis
Nelson Watts et al.
Endocrine Practice (2013)
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease
Evangelos Terpos et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Calcium supplements and cardiovascular risk in the Women's Health Initiative
M. J. Bolland et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Prevention of falls in the elderly-a review
M. K. Karlsson et al.
OSTEOPOROSIS INTERNATIONAL (2013)
High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy
B. Bouvard et al.
ANNALS OF ONCOLOGY (2012)
Bone Health in Adult Cancer Survivorship
Maryam B. Lustberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prevalence of osteoporosis among cancer patients in Germany Prospective data from an oncological rehabilitation clinic
M. Reuss-Borst et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
R. Rizzoli et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
P. Hadji et al.
ANNALS OF ONCOLOGY (2011)
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
Jeong Eun Kim et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
Antonella L. Rastelli et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Guidelines for the diagnosis and management of multiple myeloma 2011
Jennifer M. Bird et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Aging and Osteoporosis in Breast and Prostate Cancer
Ari VanderWalde et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Osteoporosis Canada 2010 Guidelines for the Assessment of Fracture Risk
Brian Lentle et al.
CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES (2011)
UK Guidance Document: Treatment of Metastatic Breast Cancer
R.E. Coleman et al.
CLINICAL ONCOLOGY (2011)
Consensus on the utility of bone markers in the malignant bone disease setting
Robert Coleman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
C. L. Shapiro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy
Hui-Lin Yang et al.
EUROPEAN RADIOLOGY (2011)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Nicolas Mottet et al.
EUROPEAN UROLOGY (2011)
American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer
Catherine H. Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Fracture Risk Assessment Tool (FRAX®): Applications in Clinical Practice
Nelson B. Watts
JOURNAL OF WOMENS HEALTH (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Management of osteoporosis in men on androgen deprivation therapy
Robert A. Adler
MATURITAS (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
S. Vasikaran et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Interpretation and use of FRAX in clinical practice
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Bisphosphonates for post-menopausal osteoporosis: are they all the same?
R. Rizzoli
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2011)
A Review of Osteoporosis Diagnosis and Treatment Options in New and Recently Updated Guidelines on Case Finding Around the World
William D. Leslie et al.
Current Osteoporosis Reports (2011)
American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast Cancer
Catherine H. Van Poznak et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer
Laura Boehnke Michaud
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
Computed Microtomography of Bone Specimens for Rapid Analysis of Bone Changes Associated with Malignancy
Daniel Chappard et al.
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY (2010)
Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer
Pamela Taxel et al.
BJU INTERNATIONAL (2010)
Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor
Peyman Hadji
BREAST CARE (2010)
High Prevalence of Low Vitamin D and Musculoskeletal Complaints in Women with Breast Cancer
Nicola Napoli et al.
BREAST JOURNAL (2010)
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Metastasis and bone loss: Advancing treatment and prevention
Robert E. Coleman et al.
CANCER TREATMENT REVIEWS (2010)
INSUFFICIENCY FRACTURES AFTER PELVIC RADIOTHERAPY IN PATIENTS WITH PROSTATE CANCER
Sefik Igdem et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Response to Questions Regarding Conclusions Reached in Age Dependence of Femoral Strength in White Women and Men
Tony M. Keaveny
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer
Shabbir M. H. Alibhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
JOURNAL OF UROLOGY (2010)
Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer
Philip J. Saylor et al.
JOURNAL OF UROLOGY (2010)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
Kathryn H. Schmitz et al.
MEDICINE & SCIENCE IN SPORTS & EXERCISE (2010)
Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group
R. K. Chaganti et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Development and use of FRAXA® in osteoporosis
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Assessment of Individual Fracture Risk: FRAX and Beyond
Joop P. W. van den Bergh et al.
Current Osteoporosis Reports (2010)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E. Terpos et al.
ANNALS OF ONCOLOGY (2009)
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer
Mirieme Ghazi et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2009)
Pathological fracture prediction in patients with metastatic lesions can be improved with quantitative computed tomography based computer models
Esther Tanck et al.
BONE (2009)
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Georgiana K. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
Peyman Hadji
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Clinical Value of Monitoring BMD in Patients Treated With Bisphosphonates for Osteoporosis
Nelson B. Watts et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Graft-Versus-Host Disease of the CNS After Allogeneic Bone Marrow Transplantation
Ali G. Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis
Colleen M. Costelloe et al.
LANCET ONCOLOGY (2009)
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
David P. Dearnaley et al.
LANCET ONCOLOGY (2009)
Risks of osteoporosis associated with breast cancer treatment: The need to access to preventive treatment
Serge Rozenberg et al.
MATURITAS (2009)
Prevention of osteoporosis after breast cancer
David M. Reid
MATURITAS (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Quantification of Dendritic Cells and Osteoclasts in the Bone Marrow of Patients with Monoclonal Gammopathy
Nicolas Josselin et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
Peripheral or Axial Bone Density Measurements to Identify Osteoporosis in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy?
Vivek K. Wadhwa et al.
UROLOGY (2009)
Skeletal sequelae of cancer and cancer treatment
Charles J. Stava et al.
Journal of Cancer Survivorship (2009)
Update on Identifying and Managing Osteoporosis in Women With Breast Cancer
Deanna Sanchez Yamamoto et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2009)
Practical guidance for the management of aromatase inhibitor-associated bone loss
P. Hadji et al.
ANNALS OF ONCOLOGY (2008)
Biomarkers of clinical trials using molecular inhibitors and radiotherapy: State-of-the-art approaches - Preface
Robert G. Bristow
CANCER AND METASTASIS REVIEWS (2008)
Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
David M. Reid et al.
CANCER TREATMENT REVIEWS (2008)
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
James E. Lester et al.
CLINICAL CANCER RESEARCH (2008)
Meta-analysis: Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer
Philip Shie et al.
CLINICAL NUCLEAR MEDICINE (2008)
Vertebral fracture assessment (VFA) with a densitometer predicts future, fractures in elderly women unselected for osteoporosis
Eugene V. McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Georgiana K. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
Richard Eastell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer
Fred Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
Adam Brufsky et al.
ONCOLOGIST (2008)
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors
Kelli Gibson et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2008)
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
M. Aapro et al.
ANNALS OF ONCOLOGY (2008)
Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club
J. J. Body et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women
Eugene V. McCloskey et al.
EUROPEAN JOURNAL OF CANCER (2007)
Bone metastasis: pathogenesis and therapeutic implications
Philippe Clezardin et al.
CLINICAL & EXPERIMENTAL METASTASIS (2007)
Aromatase inhibitors and bone
Richard Eastell
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Vitamin D deficiency
Michael F. Holick
NEW ENGLAND JOURNAL OF MEDICINE (2007)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
Simona Colla et al.
BLOOD (2007)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer
Juan Morote et al.
UROLOGY (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Some musculo-skeletal sequelae in cancer survivors
Liv Hege Aksnes et al.
ACTA ONCOLOGICA (2007)
International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients
Jean-Jacques Body et al.
EUROPEAN JOURNAL OF CANCER (2007)
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study
J. Geisler et al.
EUROPEAN JOURNAL OF CANCER (2006)
Nutrition and physical activity during and after cancer treatment: An American Cancer Society guide for informed choices
Colleen Doyle et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2006)
Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E. Coleman
CLINICAL CANCER RESEARCH (2006)
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCICCTG MA.17
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma
Martha Q. Lacy et al.
MAYO CLINIC PROCEEDINGS (2006)
Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Alpha CTX as a biomarker of skeletal invasion of breast cancer:: Immunolocalization and the load dependency of urinary excretion
Diana J. Leeming et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression
J Morote et al.
JOURNAL OF UROLOGY (2006)
Effects of third-generation aromatase inhibitors on bone
Eugene McCloskey
EUROPEAN JOURNAL OF CANCER (2006)
The role of bisphosphonates in the treatment of prostate cancer: Recommendations from an expert panel
Fred Saad et al.
CLINICAL GENITOURINARY CANCER (2006)
Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy
JM Bruder et al.
UROLOGY (2006)
Prostate cancer, osteoporosis and fracture risk
TJ Allain
GERONTOLOGY (2006)
Predicting the strength of femoral shafts with and without metastatic lesions
JH Keyak et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz et al.
LANCET (2005)
Breast cancer metastasis: Markers and models
B Weigelt et al.
NATURE REVIEWS CANCER (2005)
被撤回的出版物: Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: A randomized controlled trial (Retracted article. See vol. 30, pg. 2328, 2015)
Y Sato et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial
G El-Hajj Fuleihan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial
N Kohno et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
VB Shahinian et al.
CANCER (2005)
Fracture risk among breast cancer survivors - Results from the Women's Health Initiative Observational Study
Z Chen et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
How to prevent steroid induced osteoporosis
PN Sambrook
ANNALS OF THE RHEUMATIC DISEASES (2005)
American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma
JL Harrouseau et al.
ANNALS OF ONCOLOGY (2005)
Mechanisms of disease: Mechanisms of bone metastasis
GD Roodman
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial
MR Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Osteoporosis and spinal fractures in men with prostate cancer: Risk factors and effects of androgen deprivation therapy
TH Diamond et al.
JOURNAL OF UROLOGY (2004)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor
Y Lu et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer
PR Sieber et al.
JOURNAL OF UROLOGY (2004)
A family history of fracture and fracture risk: a meta-analysis
JA Kanis et al.
BONE (2004)
Corticosteroid-induced osteoporosis
A El Maghraoui
PRESSE MEDICALE (2004)
Patterns of relapse and modalities of treatment of breast cancer: The 'IRIS' project, a multicenter observational study
M Cazzaniga et al.
ONCOLOGY (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Osteoporosis and prostate cancer
MA Moyad
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2003)
CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease
J Barretina et al.
ANNALS OF HEMATOLOGY (2003)
Management of treatment-related osteoporosis in men with prostate cancer
MR Smith
CANCER TREATMENT REVIEWS (2003)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
Serum estradiol level and risk of breast cancer during treatment with raloxifene
SR Cummings et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients.: The effect of adjuvant clodronate treatment
L Vehmanen et al.
EUROPEAN JOURNAL OF CANCER (2001)
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
SF Shariat et al.
UROLOGY (2001)
Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens
S Granchi et al.
PROSTATE (2001)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
CM Klotzbuecher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
The vascular system - An overview of structure and function
MK Pugsley et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2000)
Mechanisms of osteoporosis after hematopoietic cell transplantation
KN Weilbaecher
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Preanalytical variability of biochemical markers of bone turnover
R Hannon et al.
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
